Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Director | May 03, 2024 | May 07, 2024 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date May 03, 2024 · Filed May 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,203 |
Reported balance
After 2024-05-03 transaction · row 1
1 source rowRow 1 · 2024-05-03 · Exercise / conversion · Acquired 732 · Balance 22,203 F1: Restricted stock units convert into common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-05-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-03 · Exercise / conversion · Disposed 732 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: The shares subject to this restricted stock unit award vested in full on May 3, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $122.13 · Expires 2034-05-06 | Direct | 7,557 |
Reported balance
After 2024-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-06 · Grant · Acquired 7,557 · Balance 7,557 F3: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: The shares subject to this restricted stock unit award vested in full on May 3, 2024.
F3: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
Seres Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07 | Direct | 6,500 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 16:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001193125-26-300924 · ownership.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2036-07-07 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 7,508 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-295071 · ownership.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,508 Underlying: Common Stock · 7,508 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:38 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 11,470 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0000950170-25-093285 · ownership.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,470 Underlying: Common Stock · 11,470 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026, provided that if the issuer's 2026 annual meeting of stockholders occurs before July 1, 2026, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000950170-25-053247 · ownership.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option vests in full on the earlier of April 10, 2026 or the day immediately prior to the company's 2026 annual meeting of shareholders. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 114,782 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-24-081521 · ownership.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,782 Underlying: Common Stock · 114,782 shares Expires 2034-06-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2024, January 1, 2025, April 1, 2025 and July 1, 2025, provided that if the Company's 2025 annual meeting of stockholders occurs before July 1, 2025, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 7,557 | $0.00 Strike: $122.13 | $0.00 |
DisclosureSEC source: 0001127602-24-014476 · form4.xml · derivative · entry 3 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,557 Underlying: Common Stock · 7,557 shares Expires 2034-05-06 F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| May 03, 2024 Filed May 7, 2024 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 732 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014476 · form4.xml · derivative · entry 2 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on May 3, 2024. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on May 3, 2024. Read SEC document |
| May 03, 2024 Filed May 7, 2024 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 732 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-014476 · form4.xml · nonDerivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0000950170-24-042653 · ownership.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-04-03 F1 · derivative.exercise_date: The option vests in full on the earlier of April 4, 2025 or the day immediately prior to the company's 2025 annual meeting of shareholders. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:25 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0000899243-23-016402 · doc4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 732 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014675 · form4.xml · derivative · entry 2 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732 Underlying: Common Stock · 732 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,601 | $0.00 Strike: $130.14 | $0.00 |
DisclosureSEC source: 0001127602-23-014675 · form4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,601 Underlying: Common Stock · 4,601 shares Expires 2033-05-03 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013920 · form4.xml · derivative · entry 2 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 670 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2023. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2023. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-013920 · form4.xml · nonDerivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-22-023973 · doc4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012859 · form4.xml · derivative · entry 4 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670 Underlying: Common Stock · 670 shares Expires not disclosed F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,061 | $0.00 Strike: $142.52 | $0.00 |
DisclosureSEC source: 0001127602-22-012859 · form4.xml · derivative · entry 3 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Underlying: Common Stock · 4,061 shares Expires not disclosed F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F3 · derivative.expiration_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012859 · form4.xml · derivative · entry 2 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012859 · form4.xml · nonDerivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | GiftCommon Stock | 2,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-024108 · form4.xml · nonDerivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,098 F1 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0000899243-21-024998 · doc4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014770 · form4.xml · derivative · entry 2 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Underlying: Common Stock · 703 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,081 | $0.00 Strike: $178.68 | $0.00 |
DisclosureSEC source: 0001127602-21-014770 · form4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Underlying: Common Stock · 4,081 shares Expires 2031-04-28 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:02 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | OtherCommon Stock | 3,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032202 · doc4.xml · nonDerivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,589 F1 · kind: Represents the receipt of shares by the reporting person pursuant to a pro rata distribution-in-kind, without consideration, of shares of the Issuer's common stock effected on November 23, 2020 by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:13 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0000899243-20-017357 · doc4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 21:50 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 18,270 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001127602-20-014900 · form4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,270 Underlying: Common Stock · 18,270 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 23:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0000899243-19-021170 · doc4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-08-04 F1 · derivative.exercise_date: The option will vest in four equal installments on each anniversary of August 5, 2019 or in full immediately prior to the occurrence of a change in control. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 54,660 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001127602-19-023012 · form4.xml · derivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,660 Underlying: Common Stock · 54,660 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries G Preferred Stock · Derivative | 22,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030863 · doc4.xml · derivative · entry 2 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionCommon Stock | 22,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030863 · doc4.xml · nonDerivative · entry 1 Berenson Stephen · CIK 0001760671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.